ZA200208738B - Stabilized aqueous suspensions for parenteral use. - Google Patents

Stabilized aqueous suspensions for parenteral use.

Info

Publication number
ZA200208738B
ZA200208738B ZA200208738A ZA200208738A ZA200208738B ZA 200208738 B ZA200208738 B ZA 200208738B ZA 200208738 A ZA200208738 A ZA 200208738A ZA 200208738 A ZA200208738 A ZA 200208738A ZA 200208738 B ZA200208738 B ZA 200208738B
Authority
ZA
South Africa
Prior art keywords
aqueous suspensions
parenteral use
stabilized aqueous
stabilized
parenteral
Prior art date
Application number
ZA200208738A
Other languages
English (en)
Inventor
Giuseppe Colombo
Alessandro Martini
Lloyd E Fox
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa
Publication of ZA200208738B publication Critical patent/ZA200208738B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200208738A 2000-05-15 2002-10-29 Stabilized aqueous suspensions for parenteral use. ZA200208738B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use

Publications (1)

Publication Number Publication Date
ZA200208738B true ZA200208738B (en) 2003-10-29

Family

ID=24283530

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208738A ZA200208738B (en) 2000-05-15 2002-10-29 Stabilized aqueous suspensions for parenteral use.

Country Status (30)

Country Link
US (3) US6495534B2 (ru)
EP (1) EP1282402B1 (ru)
JP (1) JP4205341B2 (ru)
KR (1) KR100828957B1 (ru)
CN (1) CN100473376C (ru)
AR (3) AR029924A1 (ru)
AT (1) ATE313316T1 (ru)
AU (2) AU2001267371B2 (ru)
BR (1) BR0110841A (ru)
CA (1) CA2409059C (ru)
CZ (1) CZ303872B6 (ru)
DE (1) DE60116084T2 (ru)
DK (1) DK1282402T3 (ru)
EA (1) EA007682B1 (ru)
EE (1) EE05376B1 (ru)
ES (1) ES2254443T3 (ru)
HK (1) HK1054194B (ru)
HU (1) HU229800B1 (ru)
IL (2) IL152537A (ru)
IN (1) IN224279B (ru)
MX (1) MXPA02011195A (ru)
NO (1) NO332215B1 (ru)
NZ (1) NZ522324A (ru)
PE (1) PE20011322A1 (ru)
PL (1) PL203075B1 (ru)
SI (1) SI1282402T1 (ru)
SK (1) SK287641B6 (ru)
TW (1) TWI256310B (ru)
WO (1) WO2001087266A1 (ru)
ZA (1) ZA200208738B (ru)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
EP1545994B1 (en) 2002-08-21 2006-11-15 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
EP1560577A2 (en) * 2002-11-08 2005-08-10 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
WO2004089335A2 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
CA2537702C (en) 2003-09-03 2012-01-03 Miscon Trading S.A. Methods for the treatment of endometriosis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
AU2005285040A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
CA2642577A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
CA2669727C (en) * 2006-09-27 2014-10-28 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP2721140B1 (en) 2011-06-19 2016-11-23 Abogen, Inc. Devices, solutions and methods for sample collection
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2924335A1 (en) 2013-09-17 2015-03-26 Terapio Corporation Methods of preventing or treating mucositis using rlip76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3423036B1 (en) 2016-03-02 2022-01-26 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
KR102438425B1 (ko) * 2016-05-06 2022-09-01 이글 파마슈티컬즈 인코포레이티드 풀베스트란트 제제 및 그의 사용 방법
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
EP3678637A1 (en) * 2017-09-07 2020-07-15 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US20200281939A1 (en) * 2017-09-07 2020-09-10 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
BR112020009141A2 (pt) * 2017-11-08 2020-10-27 Eagle Pharmaceuticals, Inc. método para tratar câncer de mama num indivíduo
MX2020007368A (es) * 2018-01-11 2020-10-12 Viropharma Biologics Llc Composiciones estables de corticosteroides.
CA3111901A1 (en) * 2018-09-07 2020-03-12 Prakash SUNDARAMURTHI Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
CA3120708A1 (en) 2018-11-20 2020-05-28 Spectrum Solutions, Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) * 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022245939A1 (en) * 2021-05-19 2022-11-24 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
ES2062310T3 (es) * 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
KR100408229B1 (ko) 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
ATE254918T1 (de) 1998-04-02 2003-12-15 Akzo Nobel Nv Orale flüssige lösung enthaltend das antidepressivum mirtazapine
PT1491208E (pt) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
US20030130245A1 (en) 2003-07-10
AU6737101A (en) 2001-11-26
EA007682B1 (ru) 2006-12-29
PE20011322A1 (es) 2002-01-10
IL165888A0 (en) 2006-01-15
ATE313316T1 (de) 2006-01-15
NO20025431D0 (no) 2002-11-13
IL152537A (en) 2007-06-17
HU229800B1 (en) 2014-07-28
HUP0302021A3 (en) 2011-03-28
TWI256310B (en) 2006-06-11
NZ522324A (en) 2005-02-25
CA2409059C (en) 2006-04-18
KR100828957B1 (ko) 2008-05-13
PL365793A1 (en) 2005-01-10
CN100473376C (zh) 2009-04-01
KR20030020280A (ko) 2003-03-08
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
US6495534B2 (en) 2002-12-17
JP4205341B2 (ja) 2009-01-07
IL152537A0 (en) 2003-05-29
AR111695A2 (es) 2019-08-07
PL203075B1 (pl) 2009-08-31
EA200201208A1 (ru) 2003-04-24
MXPA02011195A (es) 2003-03-10
AR029924A1 (es) 2003-07-23
EE200200631A (et) 2004-04-15
DE60116084T2 (de) 2006-08-17
BR0110841A (pt) 2003-03-11
CA2409059A1 (en) 2001-11-22
US20030114430A1 (en) 2003-06-19
JP2003533467A (ja) 2003-11-11
EP1282402A1 (en) 2003-02-12
NO332215B1 (no) 2012-07-30
IN224279B (ru) 2005-02-25
SK15982002A3 (sk) 2003-05-02
HUP0302021A2 (hu) 2003-09-29
HK1054194B (zh) 2010-02-12
CZ303872B6 (cs) 2013-06-05
AU2001267371B2 (en) 2006-01-05
ES2254443T3 (es) 2006-06-16
HK1054194A1 (en) 2003-11-21
EP1282402B1 (en) 2005-12-21
AR098830A2 (es) 2016-06-15
SI1282402T1 (sl) 2006-04-30
SK287641B6 (sk) 2011-05-06
CN1429101A (zh) 2003-07-09
WO2001087266A1 (en) 2001-11-22
US20020115645A1 (en) 2002-08-22
NO20025431L (no) 2003-01-13
EE05376B1 (et) 2011-02-15
DK1282402T3 (da) 2006-05-08

Similar Documents

Publication Publication Date Title
ZA200208738B (en) Stabilized aqueous suspensions for parenteral use.
ZA200207331B (en) Ethylenediamine derivatives.
MXPA03002269A (es) Derivados de purina.
MXPA03005270A (es) Derivados de piperazina.
MXPA03002410A (es) 4-amino-quinazolinas.
MXPA03000078A (es) Derivados de purina.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
ZA200007669B (en) Insert.
MXPA03002256A (es) Factor viii modificado.
EG23262A (en) Delta -pyrrolines.
HK1044363A1 (en) Headlight.
HK1051863A1 (en) Indol-3-yl derivatives.
HK1055426A1 (en) Indoloquinazolinones.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03005714A (es) Sulfamidotienopirimidinas.
HUP0300562A3 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the
MXPA03004453A (es) Derivados de pirimidina.
HK1050889A1 (en) Substituted aminomehyl-phenyl-cyclohexane derivatives.
HK1052925A1 (en) Substituted 1-aminobutan-3-ol derivatives.
MXPA03002411A (es) 4-amino-quinazolinas.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.
HK1061560A1 (en) Triazolo-epothilones.
MXPA03008394A (es) Derivados de biuretano.